HCW Biologics Exercised Option to Regain Full Rights for Two Commercial-Ready Reagents from Wugen
Globe Newswire (Wed, 27-May 7:45 AM ET)
Globe Newswire (Fri, 22-May 4:02 PM ET)
Globe Newswire (Thu, 21-May 9:53 AM ET)
Biologics Market Momentum Accelerates Across Healthcare, AI, And Global Medical Tourism
Globe Newswire (Fri, 15-May 10:14 AM ET)
HCW Biologics Reports First Quarter 2026 Business Highlights and Financial Results
Globe Newswire (Thu, 14-May 4:25 PM ET)
Globe Newswire (Thu, 14-May 7:30 AM ET)
HCW Biologics Announces Adjournment of Special Meeting of Stockholders Due to Lack of Quorum
Globe Newswire (Thu, 30-Apr 4:20 PM ET)
Globe Newswire (Mon, 27-Apr 7:30 AM ET)
Globe Newswire (Tue, 31-Mar 5:05 PM ET)
Globe Newswire (Tue, 17-Mar 7:50 AM ET)
HCW Biologics Inc is a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to support or treat diseases promoted by chronic inflammation. It has created novel compounds that represent a new class of drugs that it believes has the potential to fundamentally change the treatment of autoimmune disorders and other proinflammatory diseases, cancer and senescence-associated dysplasia. The company has developed two proprietary drug discovery and development platforms which it uses to create novel fusion immunotherapeutics: The TOBI (Tissue factOr-Based fusIon) platform, and The T-cell Receptor Beta Chain constant region (TRBC) platform. It operates and manages its business as one reportable segment.
HCW Biologics trades on the NASDAQ stock market under the symbol HCWB.
As of June 11, 2026, HCWB stock price climbed to $1.32 with 581,514 million shares trading.
HCWB has a beta of 2.31, meaning it tends to be more sensitive to market movements. HCWB has a correlation of 0.02 to the broad based SPY ETF.
HCWB has a market cap of $9.45 million. This is considered a Sub-Micro Cap stock.
In the last 3 years, HCWB traded as high as $100.80 and as low as $.25.
The top ETF exchange traded funds that HCWB belongs to (by Net Assets): VXF.
HCWB has underperformed the market in the last year with a price return of -76.0% while the SPY ETF gained +23.6%. However, in the short term, HCWB had mixed performance relative to the market. It has outperformed in the last 3 months, returning +134.9% vs +9.2% return in SPY. But in the last 2 weeks, HCWB shares have been beat by the market, returning -32.0% compared to an SPY return of -1.7%.
HCWB support price is $1.02 and resistance is $1.40 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that HCWB shares will trade within this expected range on the day.